Cirrhosis has been associated with decreased responsiveness to several vaccines. In a retrospective study of 26,082 patients with cirrhosis, participants who received three doses of a coronavirus disease 2019 (COVID-19) mRNA vaccine when Delta and Omicron were the predominant variants had an 80.7% reduction in COVID-19 incidence (95% CI 39.2–89.1, P < 0.001) compared with matched controls who only received two doses.
References
Original article
John, B. V. et al. Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.07.036 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. Investigating two versus three doses of mRNA vaccine in patients with cirrhosis. Nat Rev Gastroenterol Hepatol 19, 752 (2022). https://doi.org/10.1038/s41575-022-00711-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00711-w
